1. Case report of the successful use of semaglutide to achieve target BMI prior to renal transplant in two patients with end-stage-kidney-disease.
- Author
-
Wallace R, Hamblin PS, Tully E, Tran J, Nelson C, and Levidiotis V
- Subjects
- Humans, Middle Aged, Treatment Outcome, Male, Female, Renal Dialysis, Glucagon-Like Peptide-1 Receptor agonists, Time Factors, Kidney Transplantation adverse effects, Kidney Failure, Chronic therapy, Kidney Failure, Chronic surgery, Kidney Failure, Chronic complications, Glucagon-Like Peptides therapeutic use, Glucagon-Like Peptides adverse effects, Obesity complications, Body Mass Index, Weight Loss drug effects, Waiting Lists
- Abstract
The following cases demonstrate a proof of concept for the safe and effective use of the glucagon-like-peptide-1 receptor agonist (GLP-1 RA) semaglutide for weight loss in obese, non-diabetic, end stage kidney disease (ESKD) patients on haemodialysis (HD), who are unable to undergo renal transplantation due to obesity. Obesity is a common barrier to wait-listing for renal transplantation with effective, broadly applicable weight loss strategies lacking. GLP-1 RAs have been shown to be effective adjuncts to achieve weight loss in non-diabetic obese people. However, the major clinical trials excluded patients with ESKD on dialysis. This paper outlines the successful use of semaglutide to achieve a target body mass index (BMI) prior to renal transplant wait-listing in two obese, non-diabetic, HD patients. These patients achieved a 16% and 12.6% weight loss in under 9 months with one now waitlisted and the other transplanted. This strategy has the potential for broader use in this patient cohort to improve wait-list times by overcoming this common barrier to renal transplantation., (© 2024 Asian Pacific Society of Nephrology.)
- Published
- 2024
- Full Text
- View/download PDF